Tenax Therapeutics Inc Share Price Nasdaq
Equities
US88032L1008
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.23M 488M |
---|---|---|---|---|---|
Net income 2024 * | -19M -1.49B | Net income 2025 * | -18M -1.41B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.39
x | P/E ratio 2025 * |
-0.86
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 13/07/21 | |
Director of Finance/CFO | 69 | 01-10 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 14/01/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 03/04/14 |
June Almenoff
BRD | Director/Board Member | 67 | 24/02/21 |
Declan Doogan
BRD | Director/Board Member | 72 | 24/02/21 |
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.44B | |
+41.93% | 40.03B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.29B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |